Drug therapy for cancer pain

Bonica JJ . Treatment of cancer pain: current status andfuture needs. In: Fields HL , Dubner R , Cervero F , eds. Advances in pain research and therapy, vol. 9. New York: Raven Press, 1985;589-589.

World Health Organization . Cancer pain relief. Geneva: World Health Organization, 1986.

Ventafridda V , Tamburini M , DeConno F . Comprehensive treatment in cancer pain. In: Fields HL , Dubner R , Cervero F , eds. Advances in pain research and therapy, vol 9. New York: Raven Press, 1985:614-617.

Ventafridda V , Tamburini M , Caraceni A , et al. Avalidation study of the WHO method for cancerpain relief. Cancer 1987;59:850-850

Sunshine A , Olson NZ , Non-narcotic analgesics. In: Wall PD , Melzack R , eds. Textbook of pain, 2nd ed. New York: Churchill Livingstone, 1989;670-670.

Twycross RG , Lack SA . Symptom control in far advanced cancer: pain relief. London: Pitman, 1983.

Foley KM . The treatment of cancer pain.N Engl J Med 1985:313:84-84.

Houde RW . Analgesic effectiveness of the narcotic agonist-antagonists. Brit J Clin Phann 1979;7:297S-297S.

Peterson GM , Randall CTC , Paterson J . Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Chin Pharmacol 1990; 38:121-121.

Osborne JR , Joel SP , Slevin ML . Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 1986:292:1548-1548.

Plummer JL , Gourlay GK , Cherry DA , Cousins MJ . Estimation of methadone clearance: application in the management of cancer pain. Pain 1988;33:313-313.

Coyle N , Adelhardt J , Foley KM , Portenoy R . Character of terminal illness in the advanced cancer patient: pain andother symptoms in the last 4 weeks of life. J Pain Symptom Manage 1990;5:83-83.

Portenoy RK , Moulin DE , Rogers A , Inturrisi CE , Foley KM . Intravenous infusion of opioids in cancer pain: clinical review and guidelines for use. Cancer Treat Rep 1986;70:575-575.

Bruera E , Brenneis C , MacDonald RN .Continuoussc infusionofnarcotics for the treatment of cancer pain: an update. Cancer Treat Rep 1987;7l:953-953.

Payne R . Role of epidural and intrathecal narcotics and peptides in the management of cancerpain. Med Clin North Am 1987;71:313-313.

Waldman SD . Implantable drug delivery systems--practical considerations. J Pain1. Bonica JJ. Treatment of cancer pain: current status andfuture needs. In: Fields HL , Dubner R , Cervero F , eds. Advances in pain research and therapy, vol. 9. New York: Raven Press, 1985;589-589.

Portenoy RK , Maidonado M , Fitzmartin R , Kaiko R , Kanner R . Controlled-release morphine sulfate: analgesic efficacy and side-effects of a 100 mg tablet in cancer pain patients. Cancer 1989;63:2284-2284.

Brescia FJ , Walsh M , Savarese JJ , Kaiko RF . Astudy ofcontrolled release oral morphine(MS Contin) in an advanced cancer hospital. J Pain Symptom Manage 1987;2: 193-193.

Swanson G , Smith J , Bulich R , New P , Shiffman R . Patient-controlled analgesia for chronic cancerpain in the ambulatory setting: a report of 117 patients. J Clin Oncol 1989;7:1903-1903,

Portenoy RK , Hagen NA . Breakthrough pain: definition, prevalence andcharacteristics, Pain 1990;41:273-273,

Houde RW . Misinformation: side effects and drug interactions. In: Hill CS , Fields WS , eds. Advancesin pain research and therapy, vol. 11, New York: Raven Press, 1989;145-145.

Kaiko RF . Commentary: equianalgesic dose ratio ofintramuscular/oralmorphine, 1:6 versus 1:3. In: Foley KM . hnturriski CE , eds. Advances in pain research and therapy, vol. 8. New York: Raven Press, 1986;87-87.

Bruera E , Chadwick S , Brenneis C , Hanson J , Macdonald RN . Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987;71:67-67.

Bruera E , Roca E , Cedaro L , Carraro S , Chacon R . Action oforal methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-751.

Ettinger AB , Portenoy RK . The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 1988;3:99-99.

Monks, R , Merskey H . Psychotropic drugs. In PD Wall , Melzack R (eds). Textbook of Pain, 2nd Ed. New York: Churchill Livingstone, 1989, pp 702-721.

Swerdlow M . Anticonvulsant drugs and chronic pain. Chin Neuropharmacol 1984:7:51-51.

Lindstrom P . Lindblom U . The analgesic effect of tocalnide in trigeminal neuralgia. Pain 1987;28:45-45.

Dejgard A , Petersen P , Kastrup J . Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988:1:9-9.

Beaver WT , Wallenstein SM , Houde RW , Rogers A . Acomparison of the analgesic effects of methotrimeprazine andmorphine in patients with cancer. Chin Pharm Ther 1966;7:436-436.

Martin WR , Jasinski DR . Physiological parameters of morphine dependence in mantolerance, early abstinence, protracted abstinence. J Psychol Res 1969;7:9-9.

Kanner RM , Foley KM . Patternsof narcotic drug use in a cancer pain clinic. Ann NYAcad Sci 1981:362: 161-161.

Jaffe il-I . Drug addiction anddrug abuse. In: Gilman AG , Goodman LS . Rail, TW , Murad F , eds. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan Publishing Co., 1985:532-532.